LPTX LPTX

Leap Therapeutics Stock Price

2.65
0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
2.65
Volume 0
Bid Price 2.55
Ask Price 2.65
News -
Day High

Low
1.33

52 Week Range

High
4.17

Day Low
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Basic
Monthly Subscription
for only
$33.03
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
VAT not included
Company Name Stock Ticker Symbol Market Type
Leap Therapeutics Inc LPTX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 2.65 19:00:00
Open Price Low Price High Price Close Price Prev Close
2.65
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 2.65 USD

Period:

Draw Mode:

Leap Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 234.04M 88.32M 63.29M $ 1.50M $ - -0.81 -5.60
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 6.05M -

more financials information »

Leap Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical LPTX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.522.692.262.511,492,7950.135.16%
1 Month2.472.76992.012.421,854,5580.187.29%
3 Months2.404.172.012.945,717,5740.2510.42%
6 Months1.714.171.332.643,509,6320.9454.97%
1 Year1.774.171.332.572,148,7360.8849.72%
3 Years3.124.170.57282.341,088,310-0.47-15.06%
5 Years6.1110.250.57282.48693,794-3.46-56.63%

Leap Therapeutics Description

Leap Therapeutics Inc is a biopharmaceutical company developing novel therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. Its clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1. DKK1 is a protein that regulates the Wnt signaling pathways and enables tumor cells to proliferate and spread, as well as suppresses the immune system from attacking the tumor. The company is studying DKN-01 in multiple ongoing clinical trials in patients with esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, or prostate cancer. Its other clinical studies include P100, P102, P204, P205, and P103.


Your Recent History
NASDAQ
LPTX
Leap Thera..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.